Sugi Predict

Sugi Predict / Compounds / SCHEMBL680329

SCHEMBL680329

SCHEMBL680329

COc1cc(C)c(N)cc1Br

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.61
▸ L3MBTL1 Q9Y468 1/20 0.61
▸ GAA P10253 1/20 0.55
▸ GFER P55789 1/20 0.55
▸ MAPT P10636 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ HTR2A P28223 4/20 0.46
▸ TAAR1 Q96RJ0 3/20 0.46
▸ HTR2C P28335 1/20 0.46
▸ CYP3A4 P08684 2/20 0.44
▸ TSHR P16473 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.43
▸ GRIN2D O15399 1/20 0.42
▸ GRIN3B O60391 1/20 0.42
▸ GRIN1 Q05586 1/20 0.42
▸ GRIN2A Q12879 1/20 0.42
▸ GRIN2B Q13224 1/20 0.42
▸ GRIN2C Q14957 1/20 0.42
▸ GRIN3A Q8TCU5 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1770841 0.91 POLB (0.56) POLBL3MBTL1GAAGFERMAPT
SCHEMBL29447103 0.86 POLB (0.67) POLBL3MBTL1MAPTNPSR1HTR2A
SCHEMBL192738 0.86 POLB (0.67) POLBL3MBTL1MAPTNPSR1HTR2A
SCHEMBL3852430 0.84 POLB (0.72) POLBL3MBTL1GAAGFERMAPT
SCHEMBL3859217 0.84 POLB (0.72) POLBL3MBTL1GAAGFERMAPT
Hydrochloric Acid SCHEMBL1401340 0.84 POLB (0.64) POLBL3MBTL1MAPTNPSR1HTR2A
SCHEMBL4896660 0.84 POLB (0.78) POLBL3MBTL1GAAMAPTNPSR1
SCHEMBL2862226 0.83 L3MBTL1 (0.50) POLBL3MBTL1MAPTNPSR1HTR2A
SCHEMBL1225409 0.83 POLB (0.61) POLBL3MBTL1GAAGFERMAPT
SCHEMBL29666518 0.83 POLB (0.61) POLBL3MBTL1GAAGFERMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025096463-A1 PLK4 MODULATORS VIBLIOME THERAPEUTICS, LLC (US) 2025-05-08 — — WO disclosed
WO-2025072330-A1 KIT INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2025-04-03 — — WO disclosed
US-11952364-B2 TRK inhibitors useful as anticancer drugs TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED (CN) 2024-04-09 — — US disclosed
CN-112739691-B TRK inhibitors as anticancer agents 泰励生物科技（上海）有限公司 2023-05-23 — — CN disclosed
US-20220388983-A1 TRK INHIBITORS USEFUL AS ANTICANCER DRUGS TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED (CN) 2022-12-08 — — US disclosed
US-20220388983-A1 TRK INHIBITORS USEFUL AS ANTICANCER DRUGS TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED (CN) 2022-12-08 — — US disclosed
WO-2021191240-A1 COMBINATION THERAPY ANTABIO SAS (FR) 2021-09-30 — — WO disclosed
EP-3848365-A1 TRK INHIBITOR AS ANTI-CANCER DRUG Tyligand Bioscience (Shanghai) Limited (CN) 2021-07-14 — — EP disclosed
EP-3848365-A1 TRK INHIBITOR AS ANTI-CANCER DRUG Tyligand Bioscience (Shanghai) Limited (CN) 2021-07-14 — — EP disclosed
CN-112739691-A TRK inhibitors as anticancer agents 泰励生物科技（上海）有限公司 2021-04-30 — — CN disclosed
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 — — US disclosed
US-20120225887-A1 Glucokinase Activators TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-09-06 — — US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 — — EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 — — US disclosed
EP-2310382-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET Eli Lilly & Company (US) 2011-04-20 — — EP disclosed
EP-2294053-A2 GLUCOKINASE ACTIVATORS Takeda San Diego, Inc. (US) 2011-03-16 — — EP disclosed
WO-2010011538-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY (US) 2010-01-28 — — WO disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 — — US disclosed
US-20090286800-A1 Glucokinase Activators TAKEDA SAN DIEGO, INC. (US) 2009-11-19 — — US disclosed
WO-2009140624-A2 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. (US) 2009-11-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11952364-B2 TRK inhibitors useful as anticancer drugs NTRK1, NTRK3, MUSK POLB 2836/4885L3MBTL1 1715/4885GAA 3942/4885
US-20220388983-A1 TRK INHIBITORS USEFUL AS ANTICANCER DRUGS NTRK1, NTRK3, MUSK POLB 2836/4885L3MBTL1 1715/4885GAA 3942/4885
US-20090286800-A1 Glucokinase Activators GCK, GCKR, GALK1 POLB 2173/4885L3MBTL1 4723/4885GAA 56/4885
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC POLB 4665/4885L3MBTL1 461/4885GAA 4337/4885
US-20120225887-A1 Glucokinase Activators GCK, GCKR, GALK1 POLB 2173/4885L3MBTL1 4723/4885GAA 56/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.